In summary, although the application of PD-1 or PD-L1 antibodies showed promising outcomes in suppressing tumor growth in an OS mouse model, the effects of ICIs had limited therapeutic benefit for patients with OS in clinic trials. Here, CD274 is linked to neoplasm.